These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

618 related items for PubMed ID: 31257988

  • 1. Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα.
    Sim J, Sockolosky JT, Sangalang E, Izquierdo S, Pedersen D, Harriman W, Wibowo AS, Carter J, Madan A, Doyle L, Harrabi O, Kauder SE, Chen A, Kuo TC, Wan H, Pons J.
    MAbs; 2019; 11(6):1036-1052. PubMed ID: 31257988
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
    Voets E, Paradé M, Lutje Hulsik D, Spijkers S, Janssen W, Rens J, Reinieren-Beeren I, van den Tillaart G, van Duijnhoven S, Driessen L, Habraken M, van Zandvoort P, Kreijtz J, Vink P, van Elsas A, van Eenennaam H.
    J Immunother Cancer; 2019 Dec 04; 7(1):340. PubMed ID: 31801627
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
    Treffers LW, Ten Broeke T, Rösner T, Jansen JHM, van Houdt M, Kahle S, Schornagel K, Verkuijlen PJJH, Prins JM, Franke K, Kuijpers TW, van den Berg TK, Valerius T, Leusen JHW, Matlung HL.
    Cancer Immunol Res; 2020 Jan 04; 8(1):120-130. PubMed ID: 31690649
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
    Piccione EC, Juarez S, Tseng S, Liu J, Stafford M, Narayanan C, Wang L, Weiskopf K, Majeti R.
    Clin Cancer Res; 2016 Oct 15; 22(20):5109-5119. PubMed ID: 27126995
    [Abstract] [Full Text] [Related]

  • 10. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL, Szilagyi K, Barclay NA, van den Berg TK.
    Immunol Rev; 2017 Mar 15; 276(1):145-164. PubMed ID: 28258703
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
    Veillette A, Chen J.
    Trends Immunol; 2018 Mar 15; 39(3):173-184. PubMed ID: 29336991
    [Abstract] [Full Text] [Related]

  • 13. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
    Puro RJ, Bouchlaka MN, Hiebsch RR, Capoccia BJ, Donio MJ, Manning PT, Frazier WA, Karr RW, Pereira DS.
    Mol Cancer Ther; 2020 Mar 15; 19(3):835-846. PubMed ID: 31879362
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
    Ring NG, Herndler-Brandstetter D, Weiskopf K, Shan L, Volkmer JP, George BM, Lietzenmayer M, McKenna KM, Naik TJ, McCarty A, Zheng Y, Ring AM, Flavell RA, Weissman IL.
    Proc Natl Acad Sci U S A; 2017 Dec 05; 114(49):E10578-E10585. PubMed ID: 29158380
    [Abstract] [Full Text] [Related]

  • 16. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
    Tahk S, Vick B, Hiller B, Schmitt S, Marcinek A, Perini ED, Leutbecher A, Augsberger C, Reischer A, Tast B, Humpe A, Jeremias I, Subklewe M, Fenn NC, Hopfner KP.
    J Hematol Oncol; 2021 Sep 27; 14(1):155. PubMed ID: 34579739
    [Abstract] [Full Text] [Related]

  • 17. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
    de Silva S, Fromm G, Shuptrine CW, Johannes K, Patel A, Yoo KJ, Huang K, Schreiber TH.
    Cancer Immunol Res; 2020 Feb 27; 8(2):230-245. PubMed ID: 31852716
    [Abstract] [Full Text] [Related]

  • 18. Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates.
    Sue M, Tsubaki T, Ishimoto Y, Hayashi S, Ishida S, Otsuka T, Isumi Y, Kawase Y, Yamaguchi J, Nakada T, Ishiguro J, Nakamura K, Kawaida R, Ohtsuka T, Wada T, Agatsuma T, Kawasaki N.
    PLoS One; 2024 Feb 27; 19(6):e0304985. PubMed ID: 38843278
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Blockade of CD47 or SIRPα: a new cancer immunotherapy.
    Murata Y, Saito Y, Kotani T, Matozaki T.
    Expert Opin Ther Targets; 2020 Oct 27; 24(10):945-951. PubMed ID: 32799682
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.